CVT-510: Began Phase II trial

CV Therapeutics Inc. (CVTX), Palo Alto, Calif. Product: CVT-510 Business: Cardiovascular Therapeutic category: Receptor agonist Target: Adenosine A1 receptors Description: Selective adenosine A1 rece...